NNE1

NNE1
Legal status
Legal status
Identifiers
CAS Number 1338925-11-3
PubChem (CID) 54752945
ChemSpider 26613275
UNII 7FVT9P642K YesY
Chemical and physical data
Formula C24H24N2O
Molar mass 356.47 g/mol
3D model (Jmol) Interactive image

NNE1 (also known as NNEI, MN-24 and AM-6527) is an indole-based synthetic cannabinoid, representing a molecular hybrid of APICA and JWH-018.[1] It was invented by Abbott and has a CB1 receptor pEC50 of 8.9 (i.e. EC50 of approximately 1nM) with around 80x selectivity over the related CB2 receptor.[2] It is suspected that metabolic hydrolysis of the amide group of NNE1 may release 1-naphthylamine, a known carcinogen, given the known metabolic liberation (and presence as an impurity) of amantadine in the related compound APINACA, and NNE1 was banned in New Zealand in 2012 as a temporary class drug to stop it being used as an ingredient in then-legal synthetic cannabis products.[3] NNE1 was subsequently found to be responsible for the death of a man in Japan in 2014.[4]

See also

References

  1. ↑ Nahoko Uchiyama; et al. (October 2014). "Characterization of four new designer drugs, 5-chloro-NNEI, NNEI indazole analog, α-PHPP and α-POP, with 11 newly distributed designer drugs in illegal products". Forensic Science International. 243: 1–13. doi:10.1016/j.forsciint.2014.03.013. PMID 24769262.
  2. ↑ Antoni R. Blaazer; et al. (October 2011). "Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: Design, synthesis, structure–activity relationships, physicochemical properties and biological activity". European Journal of Medicinal Chemistry. 46 (10): 5086–5098. doi:10.1016/j.ejmech.2011.08.021. PMID 21885167.
  3. ↑ New Zealand Government Gazette, Notice Number 7051, 1 November 2012
  4. ↑ Chizuko Sasaki; et al. (January 2015). "A case of death caused by abuse of a synthetic cannabinoid N -1-naphthalenyl-1-pentyl-1H -indole-3-carboxamide". Forensic Toxicology. 33 (1): 165–169. doi:10.1007/s11419-014-0246-5.
This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.